Wall Street brokerages expect OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings per share (EPS) of $0.09 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for OraSure Technologies’ earnings. OraSure Technologies posted earnings of $0.13 per share in the same quarter last year, which suggests a negative year over year growth rate of 30.8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, February 14th.
On average, analysts expect that OraSure Technologies will report full-year earnings of $0.42 per share for the current fiscal year, with EPS estimates ranging from $0.30 to $0.48. For the next financial year, analysts forecast that the firm will post earnings of $0.36 per share, with EPS estimates ranging from $0.34 to $0.38. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The business’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 earnings per share.
Shares of OraSure Technologies (OSUR) opened at $18.34 on Wednesday. The firm has a market capitalization of $1,110.00, a P/E ratio of 35.27, a PEG ratio of 3.63 and a beta of 1.28. OraSure Technologies has a twelve month low of $8.39 and a twelve month high of $23.01.
In other OraSure Technologies news, CEO Douglas A. Michels sold 25,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $22.55, for a total value of $563,750.00. Following the transaction, the chief executive officer now owns 743,058 shares of the company’s stock, valued at $16,755,957.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mara G. Aspinall purchased 5,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the acquisition, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The disclosure for this purchase can be found here. 6.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Pinebridge Investments L.P. bought a new position in shares of OraSure Technologies in the second quarter valued at $131,000. Victory Capital Management Inc. increased its holdings in shares of OraSure Technologies by 17.6% in the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 1,360 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of OraSure Technologies in the third quarter valued at $186,000. Profund Advisors LLC increased its holdings in shares of OraSure Technologies by 2.8% in the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 293 shares in the last quarter. Finally, ETRADE Capital Management LLC bought a new position in shares of OraSure Technologies in the second quarter valued at $193,000. 94.43% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/27/0-09-eps-expected-for-orasure-technologies-inc-osur-this-quarter.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about OraSure Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OraSure Technologies and related companies.